CLLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cellectis SA (CLLS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has bearish technical indicators, and no recent trading signals from Intellectia Proprietary Trading Signals. While the company's focus on allogenic CAR-T therapeutics is promising, there is insufficient data or momentum to justify immediate investment.
The technical indicators for CLLS are bearish. The MACD histogram is negative and contracting, RSI is neutral at 31.287, and moving averages suggest a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 3.115, with key support at 2.913 and resistance at 3.318.
Barclays initiated coverage with an Overweight rating and a $9 price target, citing the potential of Cellectis' allogenic CAR-T platform to address previously inaccessible treatment settings.
No significant trading trends from hedge funds or insiders. The stock has a bearish technical setup and lacks recent news or event-driven catalysts. Congress trading data is also absent.
No financial performance data available for the latest quarter.
Barclays has an Overweight rating with a $9 price target, indicating optimism about the company's long-term potential.
